Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 18/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | PTPRF | P10586 | 1/20 | 0.36 |
| ▸ | PTPRA | P18433 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800199 | 0.89 | PTPN1 (0.38) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL5768014 | 0.79 | PTPN1 (0.40) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL5742279 | 0.79 | MTNR1A (0.38) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL4264218 | 0.79 | MTNR1A (0.40) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL4274375 | 0.75 | ADAMTS4 (0.36) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL4806715 | 0.74 | PTPN1 (0.38) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL5187438 | 0.73 | PTPN1 (0.39) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL4267609 | 0.73 | PTPN1 (0.47) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL4260729 | 0.71 | PTPN1 (0.35) | PTPN1MTNR1AMTNR1BPTPRFPTPRA | |
| SCHEMBL4261640 | 0.70 | PTPN1 (0.38) | PTPN1MTNR1AMTNR1BPTPRFPTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358364-B2 | treatment of diabetes and/or cancer; useful in the treatment of syndrome X; capable of inhibiting Protein tyrosine phosphatase | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20040266788-A1 | Substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266788-A1 | Substituted carboxylic acids | PTP4A1, PTPRS, G6PC1 | PTPN1 11/4885MTNR1A 589/4885MTNR1B 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.